Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, randomised, double-blind, placebo- and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50microg, 100microg, 200microg) of BEA 2180 BR to tiotropium 5microg, delivered by the Respimat inhaler and placebo in patients with chronic obstructive pulmonary disease

Next Previous
X
Search
Trial Profile

A multinational, randomised, double-blind, placebo- and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50microg, 100microg, 200microg) of BEA 2180 BR to tiotropium 5microg, delivered by the Respimat inhaler and placebo in patients with chronic obstructive pulmonary disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BEA 2180-BR (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 05 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 May 2009 Additional location identified as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 1950 to 2080 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top